HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jean-François Rossignol Selected Research

nitazoxanide (NTZ)

3/2022A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19.
2/2022The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters.
7/2021The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide.
1/2021Systemic efficacy on Cryptosporidium parvum infection of aminoxanide (RM-5061), a new amino-acid ester thiazolide prodrug of tizoxanide.
6/2019A Pilot Clinical Trial of Nitazoxanide in the Treatment of Chronic Hepatitis B.
1/2017Synthesis and pre-clinical studies of new amino-acid ester thiazolide prodrugs.
5/2016Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus.
10/2014Nitazoxanide: a first-in-class broad-spectrum antiviral agent.
9/2014Analyzing the relationship of QT interval and exposure to nitazoxanide, a prospective candidate for influenza antiviral therapy--A formal TQT study.
7/2014Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jean-François Rossignol Research Topics

Disease

7Infections
02/2022 - 02/2006
5Chronic Hepatitis C
06/2009 - 01/2008
4Human Influenza (Influenza)
05/2016 - 07/2014
4Diarrhea
03/2012 - 10/2005
3COVID-19
03/2022 - 11/2021
3Cryptosporidiosis
01/2021 - 11/2009
3Chronic Hepatitis B
06/2019 - 10/2008
2Respiratory Tract Infections (Respiratory Tract Infection)
01/2017 - 05/2016
2Hepatitis C
10/2014 - 11/2009
2Hepatitis
04/2009 - 01/2008
2Enteritis
03/2006 - 10/2005
1Weight Loss (Weight Reduction)
02/2022
1Inflammation (Inflammations)
02/2022
1Coronavirus Infections
05/2016
1Yellow Fever
10/2014
1Communicable Diseases (Infectious Diseases)
10/2014
1Dengue (Dengue Fever)
10/2014
1Hepatitis B
10/2014
1Paramyxoviridae Infections (Parainfluenza)
10/2014
1Gastrointestinal Diseases (Functional Gastrointestinal Disorders)
09/2014
1Giardiasis
01/2010
1Liver Diseases (Liver Disease)
11/2009
1Anemia
03/2009
1Clostridium Infections
02/2009
1Acquired Immunodeficiency Syndrome (AIDS)
10/2008
1Coinfection
10/2008
1Amebic Dysentery (Amoebic Dysentery)
10/2007
1Amebiasis (Amoebiasis)
10/2007
1Amebic Liver Abscess
10/2007
1Colonic Neoplasms (Colon Cancer)
01/2006

Drug/Important Bio-Agent (IBA)

23nitazoxanide (NTZ)FDA Link
03/2022 - 10/2005
9Antiviral Agents (Antivirals)IBA
02/2022 - 01/2008
5Pharmaceutical PreparationsIBA
02/2022 - 02/2009
4Ribavirin (Virazole)FDA LinkGeneric
06/2009 - 10/2008
2Antiparasitic Agents (Antiparasitics)IBA
07/2021 - 01/2017
2Metronidazole (Metric)FDA LinkGeneric
01/2010 - 01/2006
2Hepatitis B Surface Antigens (HBsAg)FDA Link
04/2009 - 10/2008
2Hepatitis B e AntigensIBA
04/2009 - 10/2008
2DNA (Deoxyribonucleic Acid)IBA
04/2009 - 10/2008
2peginterferon alfa-2a (Pegasys)FDA Link
03/2009 - 10/2008
1Interferon Type IIBA
07/2021
1ProdrugsIBA
01/2021
1tizoxanideIBA
01/2021
1Amino AcidsFDA Link
01/2021
1aminoxanideIBA
01/2021
1EstersIBA
01/2021
1Neuraminidase (Sialidase)IBA
10/2014
1RNA (Ribonucleic Acid)IBA
10/2014
1Moxifloxacin (Avelox)FDA Link
09/2014
1SuspensionsIBA
03/2012
1Albendazole (Albenza)FDA Link
01/2010
1TinidazoleFDA Link
01/2010
1NitroimidazolesIBA
01/2010
1Peptide Initiation Factors (Initiation Factor)IBA
11/2009
1Protein Kinases (Protein Kinase)IBA
11/2009
1Double-Stranded RNA (RNA, Double Stranded)IBA
11/2009
1VancomycinFDA LinkGeneric
02/2009
1IsoflavonesIBA
02/2006
13- (3- bromophenyl)- 5,7- dihydroxy- 4- oxo- 4H- chromene- 2- carboxylic acid ethyl esterIBA
02/2006

Therapy/Procedure

7Therapeutics
02/2022 - 10/2007
1Oral Administration
10/2014